This cohort study analyzes data from 3 commercial claims databases to conduct near–real-time monitoring of health outcomes following BNT162b2 COVID-19 vaccination in the US pediatric population aged 5 to 17 years.
Home>>Clinical Practice Guidelines>>Safety of the BNT162b2 COVID-19 Vaccine in Children Aged 5 to 17 Years
Clinical Practice Guidelines